Jasper Therapeutics, Inc.
JSPR
$0.46
$0.00-0.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 62.58% | -0.53% | -83.25% | -54.73% | -46.68% |
| Total Depreciation and Amortization | 18.37% | -57.67% | -13.71% | -3.13% | -13.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -258.38% | -20.16% | 33.21% | 55.95% | 69.08% |
| Change in Net Operating Assets | -1,255.58% | -109.73% | 786.03% | -8.46% | 159.17% |
| Cash from Operations | -3.47% | -20.97% | -32.30% | -45.16% | -28.25% |
| Capital Expenditure | 100.00% | 100.00% | 95.54% | -- | 58.26% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 100.64% | 116.00% | 66.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 315,322.22% | 3,304.97% | -- | 1,132.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -198.55% | 315,322.22% | 3,304.97% | -- | 227.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.43% | 179.55% | 20.31% | -172.30% | -22.88% |